V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) antibody

Details for Product No. ABIN965693
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

 
Antigen
Synonyms B-RAF1, BRAF1, NS7, RAFB1, RMIL, C-RMIL, 9930012E13Rik, AA120551, AA387315, AA473386, B-raf, Braf-2, Braf2, C230098H17, C87398, D6Ertd631e, B-Raf, braf1, rafb1, b-raf1, sierrabraf, BRAF
Reactivity
Human
(177), (24), (20), (6), (4), (1), (1), (1), (1)
Host
Mouse
(110), (63), (4), (2)
Clonality (Clone)
Monoclonal ()
Conjugate
Un-conjugated
(3), (3), (3), (3), (3), (3), (3), (3), (3), (3), (3)
Application
Western Blotting (WB), Immunohistochemistry (IHC), ELISA
(120), (75), (44), (44), (30), (20), (18), (10), (4), (2), (1), (1), (1)
Pubmed 5 references available
Catalog no. ABIN965693
Quantity 0.1 mL
Price
536.25 $   Plus shipping costs $45.00
Options
Shipping to United States (Change)
Availability Will be delivered in 5 to 7 Business Days

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen Purified recombinant fragment of BRAF expressed in E. Coli.
Clone 1H12F1-1H12G10-1F12F11C9
Isotype IgG1
Purification Ascitic fluid
Alternative Name BRAF
Background BRAF(V-raf murine sarcoma viral oncogene homolog B1 ) is the main effectors recruited by GTP-bound Ras to activate the MEKMAP kinase pathway. B-Raf contains three consensus Akt phosphorylationsites (Ser364, Ser428, and Thr439).B-Raf is a key regulatory molecule of the mitogen-activated protein kinase kinase (MEK),it has a long amino-terminal region,the region is essential for homo-dimerization of B-Raf and hetero-dimerization of B-Raf and c-Raf at the plasma membrane, followed by phosphorylation of Thr118 in the amino-terminal B-Raf-specific region. Notably, in calcium ionophore-stimulated HeLa cells, B-Raf could propagate signals to MEK under the basal level of GTP-Ras. Expression of Raf-B is highly restricted with highestlevels in the cerebrum and testes and defects in braf are involved in a wide range of cancers.The BRAF gene mutation is frequently detected in papillary thyroid carcinoma,melanocytic nevi,primary cutaneous melanomas and colorectal cancers.
Synonyms: BRAF
Gene ID 673
Application Notes Western Bloting: 1/500 - 1/2000.
Immunohistochemistry: 1/200 - 1/1000.
ELISA: Propose dilution 1/10000.
Not yet tested in other applications.
Determining optimal working dilutions by titration test.
Restrictions For Research Use only
Format Liquid
Preservative Sodium azide
Storage 4 °C
Product cited in: Rapp, Goldsborough, Mark et al.: "Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 80, Issue 14, pp. 4218-22, 1983 (PubMed).

Fullen, Poynter, Lowe et al.: "BRAF and NRAS mutations in spitzoid melanocytic lesions." in: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, Vol. 19, Issue 10, pp. 1324-32, 2006 (PubMed).

Terai, Matsuda: "The amino-terminal B-Raf-specific region mediates calcium-dependent homo- and hetero-dimerization of Raf." in: The EMBO journal, Vol. 25, Issue 15, pp. 3556-64, 2006 (PubMed).

Noda, Kato, Yoshikawa et al.: "Frequent involvement of ras-signalling pathways in both polypoid-type and flat-type early-stage colorectal cancers." in: Journal of experimental & clinical cancer research : CR, Vol. 25, Issue 2, pp. 235-42, 2006 (PubMed).

Kim, Giuliano, Turner et al.: "Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma." in: Annals of surgery, Vol. 244, Issue 5, pp. 799-804, 2006 (PubMed).

Hosts (110), (63), (4), (2)
Reactivities (177), (24), (20), (6), (4), (1), (1), (1), (1)
Applications (120), (75), (44), (44), (30), (20), (18), (10), (4), (2), (1), (1), (1)
Conjugates (3), (3), (3), (3), (3), (3), (3), (3), (3), (3), (3)
Epitopes (17), (16), (13), (12), (9), (6), (4), (4), (4), (3), (2), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
back to top